SynthesisJournal of experimental & clinical cancer research : CR2023
Impact of chemotherapeutic agents on liver microenvironment: oxaliplatin create a pro-metastatic landscape.
Synthesis in Journal of experimental & clinical cancer research : CR, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 23 citations in OpenAlex.
- Natural panax notoginseng-derived nanovesicles trigger multiple cell death mechanisms and reprogram chemokine signaling to impede oral squamous cell carcinoma progression.Journal of nanobiotechnology · 2026Article
- Cellular senescence in human liver under normal aging and cancer.Cell genomics · 2026Article
- Liver microenvironment-driven immunosuppressive niche in colorectal cancer liver metastasis and its therapeutic remodeling.Frontiers in immunology · 2026Review
- Spatial Profiling and Prognostic Role of CD169+ Macrophages in Colorectal Cancer From Adjacent Nontumor Mucosa to Liver Metastasis.Journal of immunology research · 2026Article
- Orchestrating the pre-metastatic niche: roles of stromal mediators and immune cells in metastatic progression and therapeutic targeting.Frontiers in immunology · 2026Review
- Correction: Impact of chemotherapeutic agents on liver microenvironment: oxaliplatin create a pro-metastatic landscape.Journal of experimental & clinical cancer research : CR · 2025Article
- Targeted NAT10 Degradation by PROTAC NP1192 Suppresses Hypoxia-Adaptive Glycolysis and Reinvigorates CD8ACS central science · 2025Article
- Circulating tumor cells: mechanisms and clinical significance in colorectal cancer metastasis.Molecular cancer · 2025Review
- A nomogram and random forest model for predicting liver metastasis in patients with early-onset colorectal cancer.Scientific reports · 2025Article
- Acupuncture for preventing chemotherapy-induced peripheral neuropathy: study protocol for a randomised controlled trial.BMJ open · 2025Article
- Effect of examined lymph node count on precise cancer-specific survival and effectiveness of adjuvant chemotherapy in resected colorectal cancer.Scientific reports · 2025Article
- Understanding pre-metastatic niche formation: implications for colorectal cancer liver metastasis.Journal of translational medicine · 2025Review
- Analyze the Diversity and Function of Immune Cells in the Tumor Microenvironment From the Perspective of Single-Cell RNA Sequencing.Cancer medicine · 2025Review
- Systemic Toxicity Profile of Chemotherapeutic Agents in a Wistar Rat Model: A Preliminary Report.Journal of toxicology · 2025Article
- Huaier promotes sensitivity of colorectal cancer to oxaliplatin by inhibiting METTL3 to regulate the Wnt/β‑catenin signaling pathway.Oncology reports · 2025Article
- Immune dynamics shaping pre-metastatic and metastatic niches in liver metastases: from molecular mechanisms to therapeutic strategies.Molecular cancer · 2024Review
- Pre-metastatic niche: formation, characteristics and therapeutic implication.Signal transduction and targeted therapy · 2024Review
- Spatiotemporally Controlled T-Cell Combination Therapy for Solid Tumor.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Role of T cells in liver metastasis.Cell death & disease · 2024Review
- The Role of High-Intensity Focused Ultrasound as a Local Consolidative Therapy in Multimodal Conversion Treatment for Colorectal Liver Metastases: A Case Series.Technology in cancer research & treatmentArticle
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundChemotherapeutic agents are used to control tumor proliferation. However, their influence in the pre-metastatic niche of target organs has not been well studied. Oxaliplatin (OXA) is a drug applied in standard treatments of colorectal cancer (CRC), while the direct effect of which on the pre-metastatic microenvironment of the liver remains unclear.
methodsModels of liver metastases were established with luciferase expressing CT26 cells in BALB/c and BALB/c-nude mice. Single-cell RNA Sequencing was performed to examine the immune microenvironment in the liver elicited by OXA. Immunofluorescence and flowcytometry were utilized to confirm the changes in the number of immune cells. LDH, CellTrace CFSE Cell Proliferation and apoptosis assays were conducted to explore the impact of OXA on T cells ex vivo. The correlation between chemotherapy-related lymphopenia and metastases was assessed by meta-analysis.
resultsHerein we discovered that administration of OXA prior to the occurrence of liver metastasis actually accelerated tumor development and colonization in the liver. Single-cell RNA sequencing revealed that the landscape of the liver immune microenvironment had been changed to immunosuppressive phenotype. Macrophages after the treatment of OXA exhibited a high ability to inhibit the activation of T cells. Further investigation revealed a significant decrease in the number of T cells in the liver, particularly CD8
conclusionsOur findings proposed that immunosuppressive microenvironment in liver induced by OXA enhanced liver metastasis of colorectal cancer, which highlighted a new consideration to balance the pro metastases and anti-cancer possibility of OXA treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.